Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target

Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc.

ODTX

0.00

Oppenheimer analyst Jeff Jones reiterates Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform and maintains $40 price target.